Exscientia, the leading Artificial Intelligence (AI) driven pharmatech company, has appointed Ben Taylor as Chief Financial Officer. Reporting to the CEO, Andrew Hopkins, he brings a deep background in biopharmaceutical finance, fundraising, and operations to the Company’s leadership team.
It has been a year of rapid growth for Exscientia, recently entering and expanding multiple large pharma partnerships, completing a $70 million Series C financing round, and advancing the first AI-designed drug into human clinical trials earlier this year.
Ben joins Exscientia with more than two decades of experience in healthcare investment banking and executive roles, including 15 years at Goldman Sachs and Barclays in the U.S., Asia, and Europe. During this period, Ben focused on financing, strategic and cross-border transactions in the biopharmaceutical industry. Ben served as President and CFO for Tyme Technologies, a NASDAQ-listed oncology focused biotechnology company, where he oversaw the company’s advancement from Phase 1 to Phase 3. Prior to joining Exscientia, Ben was interim CFO at Aetion, a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation.
At Exscientia, Ben will be responsible for finance and legal functions, overseeing the corporate development strategy and investor relations. Operating between the Company’s HQ in Oxford, UK and Boston, Massachusetts, Ben will be instrumental in helping Exscientia establish U.S. operations.
“Ben brings a rare combination of exceptional transaction experience along with practical knowledge of biotech operations”, said Andrew Hopkins, CEO of Exscientia. “As our platform continues to scale with both internal and partnered pipeline programs, Ben’s understanding of pharmaceutical business models will be invaluable”.
Commenting on his appointment Ben said, “Exscientia is the type of company that can change how the entire industry develops drugs. Its AI systems have already shown a real-world ability to rapidly design drugs from a concept and advance them into the clinic. I’m incredibly excited to join such a talented team and develop the platform to grow a deep pipeline”.
Exscientia is a global leading Pharmatech company, using Artificial Intelligence (AI) to drive drug discovery and is the first AI company to have designed a novel molecule to enter the clinic. Founded in 2012, Exscientia fuses the power of AI with the experience of seasoned drug hunters. Exscientia’s innovative Centaur Chemist® platform enables breakthrough productivity gains as well as new approaches to improve drug design. Novel compounds are automatically designed and prioritized for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.
Exscientia’s Centaur Biologist® platform drives the flexible analysis and prioritisation of discovery targets across all pharmaceutically relevant disease space. Exscientia is collaborating with several leading pharmaceutical and life sciences companies as well as building its own portfolio of innovative medicines. Exscientia has its headquarters in Oxford, England with further offices in Dundee, Scotland, the USA and Japan. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI
Anitra Sprauten; Edelman UK
P: +44 (0)78 9685 9386
Stephanie Crisp; Edelman UK
P: +44 (0)75 8300 3417
Mark Swindells; Chief Commercial Officer